Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Large Scale Data Solutions Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
Confirmed Presenting Companies:
Speaker Profile
M.D., Chief Executive Officer, BioAro
Biography
Dr. Anmol S. Kapoor is a cardiologist, entrepreneur, and founder of BioAro, a next-generation precision health company integrating genomics, multi-omics, and advanced AI to transform clinical care. Under his leadership, BioAro has built a global ecosystem spanning whole-genome and cancer sequencing, pharmacogenomics, microbiome testing, telomere biology, and longevity sciences.Driven to bridge the gaps of traditional medicine, Dr. Kapoor is advancing a prediction-, prevention-, and personalization-focused model that empowers clinicians across cardiology, oncology, dermatology, gastroenterology, gynecology, and longevity medicine.He also founded PanOmiQ, an AI-powered therapy-selection and multi-omics platform, and pioneered BioEMRBioELR, next-generation electronic record systems integrating AI into everyday practice. Through Kapoor Wealth Partners, he supports breakthrough ventures in medtech, biotech, digital health, and longevity.Internationally recognized in digital health and multi-omics innovation, Dr. Kapoor is shaping the global adoption of data-driven, patient-centered healthcare.
Talk
Genelio: Democratizing Access to Precision Medicine
Genelio is transforming precision medicine by making multiOmics intelligence accessible to everyone. Powered by AI and LLM-driven BioIntelligence, it turns complex multi-Omics data into simple, conversational insights which enables individuals, clinicians, and researchers to understand risks, optimize health, and make informed decisions without barriers to expertise.
Large-Scale Data Solutions Showcase:
BioAro Inc.
BioAro advances longevity through AI, LLM-powered BioIntelligence, and Axion hardware, integrating genomics, multi-omics lab testing, and real-time analysis. Its PanOmiQ platform unifies DNA, microbiome, and metabolic insights to deliver predictive, personalized, and proactive precision health.
Speaker Profile
CEO & Founder, SEQSTER
Biography
Ardy Arianpour is a visionary health tech executive with 20+ years driving innovation in life sciences and digital health. In 2016, he founded SEQSTER, the leading healthcare technology company that puts the patient at the center of all their health data. SEQSTER was founded with the mission of positively impacting patient lives at scale by removing the barriers to health data access. For the first time, users create their own matched, longitudinal health data profile across all of their US-based healthcare data sources through person-centric interoperability. Ardy serves as Faculty for NextMed.Health, a Judge for the Top Tech Awards, a member of the Digital Health Advisory Board at UCSD, an Advisory Board member for Inside Precision Medicine, and a Trustee of the Fleet Science Center.
Talk
The Transformative Power of Health Data
SEQSTERs Operating System unifies fragmented health data across EHRs, labs, genomics, and wearables in real time. By creating a comprehensive, patient-centered view, SEQSTER enables researchers and healthcare organizations to generate actionable insights, accelerate clinical research, and advance precision medicine through large-scale, interoperable data connectivity.
Large-Scale Data Solutions Showcase:
SEQSTER
SEQSTER is a leading health data technology company that enables patient-centric interoperability by connecting, standardizing, and visualizing health data from any source in real time. Its Operating System empowers healthcare organizations, researchers, and patients to access complete, longitudinal health records that drive precision medicine and real-world evidence.
Speaker Profile
M.D., Ph.D., Co-Founder and CEO, N-Power Medicine
Biography
Most recently served as Senior Vice President and Global Head for Personalized Healthcare, Product Development at GenentechRoche. Prior to joining Genentech, Mark was a member of the founding leadership team and Head of Clinical Development and Medical Affairs at GRAIL, where his team built one of the largest clinical research programs in genomic medicine aimed at early cancer detection. Some of his previous roles include Lead for Oncology Clinical Sciences at Googlex Life Sciences, Chief Medical Officer at Boreal Genomics, and Vice President of Oncology Development at Genomic Health, where he led the successful development and validation of the Oncotype DX Colon and Prostate Cancer Assays.
Talk
Generation and Application of Prospective External Control Arms (ProECA)
Reducing reliance on traditional randomized trials is critical to accelerating and de-risking drug development. Broad adoption of external controls requires prospectively generated fit-for-purpose data aligned to trial designs, including trial compatible end points and prognostic covariates. N-Powers ProECA platform is already in use in early development, with future late-stage applications.
Large-Scale Data Solutions Showcase:
N-Power Medicine
N-Power Medicine is transforming drug development by embedding prospective, trial-grade research into routine oncology care.
Its network and infrastructure enable scalable Prospective External Control Arms and novel trial designs across community settings.
